# Biocon Limited (BIOCON)

> BIOCON closed at ₹351.80 on 30 Oct 2026, trailing P/E 115.8, market cap ₹57,329 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Biocon Limited (NSE: BIOCON) closed at ₹351.80 on 30 Oct 2026, -1.2% over one year, against a 52-week range of ₹321.30 – ₹447.15.

In the quarter ended 30 Jun 2026 (consolidated, filed 5 Aug 2026) it reported revenue of ₹4,336 cr and net profit of ₹141 cr, a 3.3% net margin; revenue grew 10.0% and profit grew 31.7% year on year.

On four consecutive filed quarters its trailing P/E is 115.8; since 8 May 2025 its own P/E has ranged from 52.6 to 181.3 (median 64.0), and today's reading is higher than 71% of those 366 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 1.7%, ROCE 2.8%, debt-to-equity 0.44, Piotroski F-score 6 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 10% of 63 sector peers; PBT margin higher than 5% of 63 sector peers; ROE higher than 8% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹351.80 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -9.1% / +0.6% / -1.2% |
| 52-week low – high | ₹321.30 – ₹447.15 |
| Market capitalisation | ₹57,329 cr |
| Trailing P/E | 115.8 |
| Price / book | 1.68 |
| EV / EBITDA | 20.2 |
| Earnings yield | 0.9% |
| TTM EPS | ₹3.04 |
| TTM net profit | ₹495 cr |
| Quarter revenue | ₹4,336 cr |
| Quarter net profit | ₹141 cr |
| Net margin | 3.3% |
| Revenue growth (YoY) | +10.0% |
| Profit growth (YoY) | +31.7% |
| Return on equity | 1.7% |
| ROCE | 2.8% |
| Debt / equity | 0.44 |
| Current ratio | 1.22 |
| Free cash flow | ₹196 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹95.5 cr |

## Questions

### What is the P/E ratio of Biocon Limited?

Biocon Limited's trailing P/E is 115.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 8 May 2025 its P/E has ranged 52.6–181.3.

### What were Biocon Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Biocon Limited reported revenue of ₹4,336 cr and net profit of ₹141 cr (consolidated), filed with the exchange on 5 Aug 2026.

### What is Biocon Limited's ROE?

Return on equity is 1.7% based on the balance sheet dated 31 Mar 2026.

### Does Biocon Limited have debt?

Debt-to-equity is 0.44 on the balance sheet dated 31 Mar 2026.

### What is BIOCON's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, BIOCON traded between ₹321.30 and ₹447.15.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/BIOCON

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._